Parkinson's disease (PD) is a kind of extrapyramidal nervous system denatured disease, which is mainly manifested as motor symptoms and non-motor symptoms. Among them, motor symptoms mainly include non-autonomous tremor, slow movement, walking balance dysfunction and muscle rigidity. In recent years, the quality of life of PD patients after treatment is directly affected by non-movement symptoms and more and more scholars at home and abroad attaches importance to it. At present, the related pathogenesis of non-movement symptoms have not been clarified. Some scholars pointed out that the occurrence of non-movement symptoms is controlled by multiple factors, and it is not appropriate to use a single factor perspective to observe the disease. In addition, due to the inconsistency of disease evaluation methods, many results before and after treatment are difficult to be compared with each other, which further aggravates the difficulty of mechanism research. It is worth noting that neuropsychiatric symptoms of Parkinson's disease are one of the most common non-motor symptoms, mainly including emotional disorders, intellectual cognitive disorders and impulse control disorders. At present, most of the neuropsychiatric symptoms of Parkinson's disease are symptomatic treatment, and long-term medication may interfere with the normal operation of other nervous systems, and there is a risk of liver and kidney damage. Neuropeptide is a kind of bioactive peptide widely existing in various tissues of the body, which can strengthen the connection between the nervous system and various systems of the body, and has a good regulation effect on many central nervous system diseases. Among them, substance P, neuropeptide Y, brain-derived nutritional factor, nesfatin-1 and other neuropeptides are closely related to the pathogenesis of neuropsychiatric symptoms in Parkinson's disease. According to their correlation, regulating neuropeptide may be a new breakthrough in the treatment of PD neuropsychiatric diseases.
DownLoad: